» Articles » PMID: 34252354

MiRNA Based Tumor Mutation Burden Diagnostic and Prognostic Prediction Models for Endometrial Cancer

Overview
Journal Bioengineered
Date 2021 Jul 12
PMID 34252354
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Uterus Corpus Endometrial cancer (UCEC) is the sixth most common malignant tumor worldwide. In this research, we identified diagnostic and prognostic biomarkers to reflect patients' immune microenvironment and prognostic. Various data of UCEC patients from the TCGA database were obtained. Firstly, patients were divided into a high tumor mutation burden (TMB) level group and a low TMB level group according to the level of TMB. Then, differentially expressed miRNAs between the two groups were obtained. LASSO logistic regression analysis was used to construct a diagnostic model to predict the level of TMB. Univariate, multivariate, and LASSO regression analysis were used to construct a prognostic risk signature (PRS) to predict the prognosis of UCEC patients. Twenty-one miRNAs were used to construct a diagnostic model for predicting TMB levels. The AUC values of ROC curves for 21-miRNA-based diagnostic models were 0.911 in the training set, 0.827 in the test set, and 0.878 in the entire set. This diagnostic model showed positive correlation with TMB, PDL1 expression, and the infiltration of immune cells. In addition, three prognostic miRNAs were finally used to construct the PRS. The PRS was related to the expression of multiple immune checkpoints and the infiltration of multiple immune cells. Furthermore, the PRS can also reflect the response to some commonly used chemotherapy regimens. We have established a miRNA-based diagnostic model and a prognostic model that can predict the prognosis of UCEC patients and their response to chemotherapy and immunotherapy, thus providing valuable information on the choice of treatment regimen.

Citing Articles

The interplay of sex steroid hormones and microRNAs in endometrial cancer: current understanding and future directions.

Thakur L, Thakur S Front Endocrinol (Lausanne). 2023; 14:1166948.

PMID: 37152960 PMC: 10161733. DOI: 10.3389/fendo.2023.1166948.


A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma.

Lin L, Wu X, Zhu J, Chen S, Chen Y, Lin F Comb Chem High Throughput Screen. 2022; 26(8):1503-1518.

PMID: 36165528 PMC: 10242768. DOI: 10.2174/1386207325666220926123923.


Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications.

Zhou X, Ao X, Jia Z, Li Y, Kuang S, Du C Front Oncol. 2022; 12:951864.

PMID: 36059609 PMC: 9428469. DOI: 10.3389/fonc.2022.951864.


microRNA-497 prevents pancreatic cancer stem cell gemcitabine resistance, migration, and invasion by directly targeting nuclear factor kappa B 1.

Yu Q, Xiu Z, Jian Y, Zhou J, Chen X, Chen X Aging (Albany NY). 2022; 14(14):5908-5924.

PMID: 35896012 PMC: 9365558. DOI: 10.18632/aging.204193.


Construction of a miRNA-Based Nomogram Model to Predict the Prognosis of Endometrial Cancer.

Ni L, Tang C, Wang Y, Wan J, Charles M, Zhang Z J Pers Med. 2022; 12(7).

PMID: 35887651 PMC: 9318842. DOI: 10.3390/jpm12071154.


References
1.
Wang P, Zeng Z, Shen X, Tian X, Ye Q . Identification of a Multi-RNA-Type-Based Signature for Recurrence-Free Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma. DNA Cell Biol. 2020; 39(4):615-630. DOI: 10.1089/dna.2019.5148. View

2.
Wright J, Khoury-Collado F, Melamed A . Harnessing Minimally Invasive Surgery to Improve Outcomes in Endometrial Cancer Surgery-The Robots Are Coming. JAMA Surg. 2019; 154(6):539. DOI: 10.1001/jamasurg.2018.5841. View

3.
Dragomir M, Chen B, Fu X, Calin G . Key questions about the checkpoint blockade-are microRNAs an answer?. Cancer Biol Med. 2018; 15(2):103-115. PMC: 5994554. DOI: 10.20892/j.issn.2095-3941.2018.0006. View

4.
Bica-Pop C, Cojocneanu-Petric R, Magdo L, Raduly L, Gulei D, Berindan-Neagoe I . Overview upon miR-21 in lung cancer: focus on NSCLC. Cell Mol Life Sci. 2018; 75(19):3539-3551. PMC: 11105782. DOI: 10.1007/s00018-018-2877-x. View

5.
Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View